An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai
Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.
“This is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
The stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.
Age-related macular degeneration affects upward of 15 million Americans. It occurs when the small central portion of the retina, known as the macula, deteriorates. The retina is the light-sensing nerve tissue at the back of the eye. Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.
When animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer. This protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.
Cedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body. In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.
“These induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,” said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study. “Though additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.”
The Latest on: Age-Related Macular Degeneration
via Google News
The Latest on: Age-Related Macular Degeneration
- Preventing and Treating Macular Degeneration in the Elderlyon July 19, 2019 at 10:47 am
Age-related macular degeneration (AMD) tops the list as one of the top three conditions that cause vision loss in people over the age of 60. AMD is most likely to affect seniors due to the slow ... […]
- Managed Care Opportunities and Approaches to Supporting Appropriate Selection of Treatment for Sight Preventionon July 19, 2019 at 8:51 am
Currently, up to 11 million people in the United States have some form of age-related macular degeneration (AMD), which is one of the leading causes of vision loss in older Americans. Ophthalmologists ... […]
- Review of Neovascular Age-Related Macular Degeneration Treatment Optionson July 19, 2019 at 8:51 am
Due to an aging population, visual impairment from neovascular age-related macular degeneration (nAMD) is increasing in the United States. Despite unprecedented improvements in vision preservation ... […]
- Yellow lenses to the rescue for macular degenerationon July 18, 2019 at 10:00 pm
I.L.B. Answer • Age-related macular degeneration is the leading cause of vision loss in industrialized countries. It is a degeneration of the central part of the retina, called the macula, which is ... […]
- Notal Vision Diagnostic Clinic reports completion of 6 million ForeseeHome AMD home-monitoring testson July 18, 2019 at 5:34 pm
the first FDA-cleared home-monitoring device for patients with intermediate dry Age-related Macular Degeneration (AMD) at risk for developing wet AMD. ForeseeHome uses a patented technology ... […]
- Pixium Vision announced sustained success of its PRIMA System after 12-months in dry age-related macular degeneration patientson July 17, 2019 at 10:02 pm
Data confirm better than expected interim six-month results The system is sustainably well tolerated while preserving residual peripheral vision Some patients improve their ability to identify letters ... […]
- Enrollment complete in trial of ranibizumab Port Delivery Systemon July 17, 2019 at 12:50 pm
Patient enrollment has been completed in a phase 3 trial of the ranibizumab Port Delivery System for wet age-related macular degeneration, Genentech and Roche announced. The randomized, multicenter, ... […]
- How to maintain independence at home while living with wet AMD (FCL July 17th)on July 17, 2019 at 12:19 pm
We're talking about Wet Age-related Macular Degeneration, or wet AMD, an eye disease that causes central vision loss and can lead to blindness. Celebrity Interior Designer Nate Berkus has some design ... […]
- Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registryon July 17, 2019 at 4:00 am
a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion Health Sciences, Inc. has also developed a proprietary medical ... […]
- How to design a safe home for people with wet age-related macular degenerationon July 16, 2019 at 10:58 am
"GMA" sponsor Novartis and Nate Berkus share tips for how to design a safe home for people with the disease that can cause blurred vision and often lead to blindness. ... […]
via Bing News